Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)
0.6500 x 15 0.6740 x 60
Post-market by (Cboe BZX)
0.6748 -0.0168 (-2.43%) 04/25/25 [NASDAQ]
0.6500 x 15 0.6740 x 60
Post-market 0.6740 -0.0008 (-0.12%) 19:44 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.6220
Day High
0.6916
Open 0.6600
Previous Close 0.6916 0.6916
Volume 415,400 415,400
Avg Vol 8,730,670 8,730,670
Stochastic %K 6.78% 6.78%
Weighted Alpha -86.69 -86.69
5-Day Change -0.1871 (-21.71%) -0.1871 (-21.71%)
52-Week Range 0.6036 - 51.0600 0.6036 - 51.0600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,009
  • Shares Outstanding, K 1,459
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,130 K
  • EBIT $ -25 M
  • EBITDA $ -24 M
  • 60-Month Beta 5.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.23
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -438.41
  • Most Recent Earnings $-17.39 on 11/07/24
  • Next Earnings Date 05/14/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -4.21
  • Number of Estimates 1
  • High Estimate -4.21
  • Low Estimate -4.21
  • Prior Year -360.51
  • Growth Rate Est. (year over year) +98.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6036 +11.80%
on 04/21/25
Period Open: 1.7900
3.6100 -81.31%
on 04/02/25
-1.1152 (-62.30%)
since 03/25/25
3-Month
0.6036 +11.80%
on 04/21/25
Period Open: 4.7200
4.6900 -85.61%
on 01/28/25
-4.0452 (-85.70%)
since 01/24/25
52-Week
0.6036 +11.80%
on 04/21/25
Period Open: 25.1600
51.0600 -98.68%
on 05/02/24
-24.4852 (-97.32%)
since 04/25/24

Most Recent Stories

More News
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics...

APVO : 0.6748 (-2.43%)
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SEATTLE, WASHINGTON / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology...

APVO : 0.6748 (-2.43%)
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High

The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.

VXF : 170.00 (+0.27%)
APVO : 0.6748 (-2.43%)
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

SEATTLE, WA / ACCESS Newswire / April 3, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics...

APVO : 0.6748 (-2.43%)
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care

APVO : 0.6748 (-2.43%)
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action

APVO : 0.6748 (-2.43%)
Aptevo to Participate in March Conferences

SEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...

APVO : 0.6748 (-2.43%)
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Marvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth

APVO : 0.6748 (-2.43%)
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues

APVO : 0.6748 (-2.43%)
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise...

APVO : 0.6748 (-2.43%)

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

3rd Resistance Point 0.7732
2nd Resistance Point 0.7324
1st Resistance Point 0.7036
Last Price 0.6748
1st Support Level 0.6340
2nd Support Level 0.5932
3rd Support Level 0.5644

See More

52-Week High 51.0600
Fibonacci 61.8% 31.7857
Fibonacci 50% 25.8318
Fibonacci 38.2% 19.8779
Last Price 0.6748
52-Week Low 0.6036

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective